Temelimab (also known as GNbAC1[1]) is an experimental monoclonal antibody drug for immune system conditions that neutralizes the human endogenous retrovirus envelope protein HERV-W.[2][3] It has been studied for multiple sclerosis up to phase 2b, where it was found to be safe and to reduce brain lesions.
[1] As of 2023, it is also being studied for cognitive impairment in long COVID.
[4] This medical article is a stub.
You can help Wikipedia by expanding it.